The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 13, 2024

Filed:

Jan. 29, 2018
Applicants:

Vanderbilt University, Nashville, TN (US);

The United States As Represented BY the Department of Veterans Affairs, Washington, DC (US);

Inventors:

Ambra A. Pozzi, Nashville, TN (US);

Manuel Chiusa, Nashville, TN (US);

Jack J. Hawiger, Nashville, TN (US);

Jozef Zienkiewicz, Nashville, TN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/47 (2006.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61K 45/06 (2006.01); A61P 13/12 (2006.01); C07K 14/50 (2006.01); C07K 14/705 (2006.01);
U.S. Cl.
CPC ...
C07K 14/4703 (2013.01); A61K 38/1709 (2013.01); A61K 38/1777 (2013.01); A61K 38/1825 (2013.01); A61K 45/06 (2013.01); A61P 13/12 (2018.01); C07K 14/50 (2013.01); C07K 14/70557 (2013.01); C07K 2319/02 (2013.01); C07K 2319/10 (2013.01); C07K 2319/30 (2013.01);
Abstract

Disclosed herein are compositions and methods for inhibiting collagen production mediated by the Fused in Sarcoma (FUS) ribonucleoprotein. As disclosed herein, the C terminal domain of FUS contains an uncommon nuclear localization sequence (NLS) motif called PY-NLS that binds the nuclear import receptor transportin. Phosphorylation of FUS leads to its association with transportin and nuclear translocation with consequent increased in collagen production. Therefore, disclosed herein is an isolated peptide having a transportin-binding moiety, which inhibits FUS from binding transportin, linked to a membrane translocating motif. These compositions and methods can be used to inhibit FUS-mediated collagen production, and treat fibrotic disease involving FUS-mediated collagen accumulation in kidneys and other organs displaying fibrotic diseases.


Find Patent Forward Citations

Loading…